We build great technology companies
NL-3721 AK Bilthoven
Send an email
If your company has already paying customers, we expect the following key items to be addressed in the business plan.
|Customer Problem: who has the problem and how you will solve it?||Market: how big is the market and what is the competitive landscape?|
|Product and/or service: what is the status and differentation of technology solution?||Business model: what is the monetization strategy and what is your 3 years financial forecast?|
|Finance: how much capital is needed and how the proceeds will be used?||Team: what is the background and qualifications?|
We will give you a clear view of the main obstacles for growing your business based on only 4 questions:
In case your answers on the first two questions have a score of 100%, your company is meeting its monthly targets the last 18-months consecutive and finaly your company is able to grow three times faster with the current cash flow, we are not able to add much value.
In all other cases, there needs to be work done on your strategy (question 1), on your team (question 2) on your execution (question 3). In those cases, there is also an additional capital need.
Please click for a personal discussion with one of the partners of Value Creation Capital.
In addition, Value Creation Capital and Spark Entrepreneurs Education offer jointly an acceleration program of 12 months. Ambitious tech companies (scale-ups) are supported hands-on in reaching their growth targets. Click for more information on the Program.
MILabs B.V. (Molecular Imaging Labs) provides high-end molecular imaging PET, SPECT, CT and optical instruments for biomedical research. Today these hybrid systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. Based on its preclinical success with MILabs proprietary U-SPECT technology, the G-SPECT system was developed. This clinical SPECT scanner received the 2015 Innovation of the Year award from the World Molecular Imaging Society. The ten-fold volumetric resolution improvement provides an image quality to visualize much smaller lesions than was possible before, which adds diagnostic confidence and accurate quantitative measurements to nuclear medicine imaging.
MILabs is delivering worldwide to renowned research institutions and hospitals.